TPX2 and cancer: Orth and colleagues, using the cancer genome atlas (TCGA) showed that, in a specific cohort of patients with lung adenocarcinoma, high levels of AURKA and TPX2 were associated with improved overall survival in response to taxane-based radiochemotherapy, but not in case of non-taxane-based radiochemotherapy, chemo- or radiotherapy only manifesting a AURKA/TPX2 dependent paclitaxel-mediated radiosensitization that led to improved OS in lung adenocarcinoma patients [27].